SynthesisAntimicrobial agents and chemotherapy2024
Updated antimicrobial dosing recommendations for obese patients.
Synthesis in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Differentiating Normal Healing From Infection in Total Joint Arthroplasty: An Educational and Diagnostic Tool for Emergency Providers Evaluating the Postoperative Patient.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2026Review
- Optimized Amoxicillin Dosing is Associated with Higher Helicobacter pylori Eradication in Metabolic and Bariatric Surgery Candidates: A Retrospective Cohort Study.Obesity surgery · 2026Article
- Infectious Complications in Metabolic and Bariatric Surgery: A Comprehensive Narrative Review of Pathophysiology, Prevention, and Management.Life (Basel, Switzerland) · 2026Review
- Bayesian Estimation of Vancomycin Exposure and Population Pharmacokinetics in Obese Patients.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- Prescribing Patterns and Clinical Outcomes of Ceftolozane/Tazobactam by Renal Function and Body Mass Index: A SPECTRA Real-World Multi-Country Analysis.Antibiotics (Basel, Switzerland) · 2026Article
- Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action.Open forum infectious diseases · 2026Review
- β-Lactam Antibiotics in Obese Adults: A Review of Population Pharmacokinetic Analyses.Clinical pharmacokinetics · 2026Review
- Population Pharmacokinetics and Model-Informed Dose Optimization of Teicoplanin in Adults with Hematological Malignancies.Pharmaceutics · 2026Article
- Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Obese and Nonobese Healthy Adults Following Multiple Administration.Drug design, development and therapy · 2026Article
- Impact of pediatric obesity on abdominal surgery outcome: a narrative review.Frontiers in pediatrics · 2026Review
- Link between physical activity, nutrition, and antimicrobial pharmacokinetics and therapeutic efficacy: Implications for resistance management.SAGE open medicine · 2026Review
- Delphi Consensus Among French Obesity Experts on Clinical Recommendations for Drug Prescription in Patients With Severe Obesity.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- The effects of recycling pharmaceutical formulations in laser powder bed fusion 3D printing - the influence of physical phenomena on printing performance.International journal of pharmaceutics: X · 2025Article
- Factors associated with persistent bacteraemia among patients with suspected infective endocarditis.Infection · 2025Article
- Risk Factors for Hospital Readmission Following Outpatient Parenteral Antimicrobial Therapy (OPAT).Infectious diseases and therapy · 2025Article
- Primary and Recurrent Erysipelas-Epidemiological Patterns in a Single-Centre Retrospective Analysis.Journal of clinical medicine · 2025Article
- Translating Pharmacokinetic-Pharmacodynamic Principles Into Improved Methodology for Clinical Trials That Compare Intermittent With Prolonged Infusion of Beta-Lactam Antibiotics.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Multidrug-Resistant Infections and Metabolic Syndrome: An Overlooked Bidirectional Relationship.Biomedicines · 2025Review
- Evaluation of prescribing practices and treatment failure for purulent skin and soft tissue infections in patients with obesity.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The prevalence of obesity has increased considerably in the last few decades. Pathophysiological changes in obese patients lead to pharmacokinetic (PK) and pharmacodynamic (PD) alterations that can condition the correct exposure to antimicrobials if standard dosages are used. Inadequate dosing in obese patients can lead to toxicity or therapeutic failure. In recent years, additional antimicrobial PK/PD data, extended infusion strategies, and studies in critically ill patients have made it possible to obtain data to provide a better dosage in obese patients. Despite this, it is usually difficult to find information on drug dosing in this population, which is sometimes contradictory. This is a comprehensive review of the dosing of different types of antimicrobials (antibiotics, antifungals, antivirals, and antituberculosis drugs) in obese patients, where the literature on PK and possible dosing strategies in obese adults was critically assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.